Kamada reports juvenile diabetes success

The company says that its AAT protein may halt the progression of the disease.

Kamada Ltd. (TASE: KMDA) today announced positive results of the Phase I/II clinical trial of its Alpha-1 Antitrypsin (AAT) protein, the active ingredient in its drug, Glassia, for the treatment of type 1 (juvenile onset) diabetes. Analysis of the results found that the AAT protein may halt the progression of diabetes, enable the pancreas beta cells to continue excreting insulin, providing better glucose balance, thereby lowering or even preventing serious future complications of the disease.

In view of the success of the trial and its results, Kamada is preparing further development of injectable AAT for the treatment and curing of juvenile onset diabetes, and move the drug forward for approval.

Most of the patients in the trial reported reduced use of insulin during most of the trial period, and there a corresponding reduction in the level of diabetes antibodies (specific diabetes antibodies), which may indicate a reduction in the autoimmune response in the pancreas against the pancreas.

RELATED ARTICLES

Kamada CEO David Tsur said, "We are very pleased and proud about the results of the trial and the obtaining of very encouraging evidence about the effectiveness and safety from the use of the AAT protein to treat and possibly cure juvenile diabetes. This is the first clinical proof that may result in a global breakthrough in the treatment and cure of juvenile diabetes. The quality of the results obtained moves us forward toward further development of the drug."

Tsur added, "On the basis of the quality of the excellent results achieved in the trial, and the great economic potential of this indication, the company intends to continue development of the drug for approval, thereby ensuring global leadership in the field through an innovative, primary, and breakthrough treatment for juvenile diabetes, for which there is no suitable treatment, except for the symptoms of the disease."